Developing and Testing an Opioid Taper Intervention Before Total Knee Arthroplasty: Phase 2 Intervention Development
University of Alabama at Birmingham
Summary
The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are: * Is the intervention feasible and acceptable to patients? * Does the intervention result in a decrease in opioid dose during the preoperative period? Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks * currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months * have a reliable telephone number for contact * speaks English Exclusion Criteria: * Taking opioid medications that include: * Buprenorphine * Methadone * Long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine) * Transdermal formations of opioid pain medications (e.g., fentanyl patches…
Interventions
- Behavioralopioid taper
The participant will attempt to taper their opioid dose by \~50% during the 4-6 week preoperative period
Location
- UAB Hospital-HighlandsBirmingham, Alabama